Phase 4
Completed N=16
Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia
Focal Dystonia
Source: ClinicalTrials.gov NCT00208091 ↗
Enrolled (actual)
16
Serious AEs
0.0%
Results posted
May 2014
Primary outcomePrimary: Note Errors (Related to Errors in Duration) — 8.20; 5.79 msec — p==0.06
Summary
This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neurosciences). Myobloc is a purified and diluted form of botulinum toxin used medically to relax unwanted muscle spasms and movements. The aim of the study is to determine the feasibility of quantifying change in performance following treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Note Errors (Related to Errors in Duration) |
8.20; 5.79 | =0.06 |
| PRIMARY Note Errors (Related to Errors in Loudness) |
10.06; 8.43 | =0.23 |
| SECONDARY Subjective Assessment Ratings of Change |
30 | — |
Eligibility Criteria
Inclusion Criteria
- Focal, task-specific dystonia clinically determined to be the result of a high level of musical skill and intensive performance history
Exclusion Criteria
- Neurological disorders other than dystonia
- Patients who are clinically depressed, demented or otherwise unable to perform appropriately or sit through 1 hour of testing
- Patients who have undergone pallidotomy, thalamotomy or deep brain stimulator implantations
- Patients who have who recently have taken medications with extrapyramidal or tremorogenic side effects
Data sourced from ClinicalTrials.gov (NCT00208091). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.